Shkreli's Ponzi Scheme Trifecta: Lies, Deceit And Greed
This article was originally published in Scrip
With the answer to the big question about Martin Shkreli out of the way – The FBI confirmed it didn't seize his $2m one-of-its-kind album of the American hip-hop group Wu-Tang Clan – what investors and patients likely are wondering is where do his companies, Turing Pharmaceuticals AG and KaloBios Pharmaceuticals Inc., go from here?
You may also be interested in...
KaloBios Pharmaceuticals Inc. is now free of Martin Shkreli, after the pharma 'bad boy' sold his remaining stock, and wants to get on with its work of focusing on R&D of medicines that benefit patients with rare and neglected diseases. But the firm also has some ideas it thinks could change biotech.
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.